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Abstract 
Catechol-O-methyl transferase (COMT) encodes an enzyme involved in the metabolism of 
dopamine and maps to a commonly deleted region that increases schizophrenia risk.  A non-
synonymous polymorphism (rs4680) in COMT has been previously found to be associated 
with schizophrenia and results in altered activity levels of COMT.  Using a haplotype block-
based gene-tagging approach we conducted an association study of seven COMT single 
nucleotide polymorphisms (SNPs) in 160 patients with a DSM-IV diagnosis of schizophrenia 
and 250 controls in an Australian population.  Two polymorphisms including rs4680 and 
rs165774 were found to be significantly associated with schizophrenia.  The rs4680 results in 
a Val/Met substitution but the strongest association was shown by the novel SNP, rs165774 
which may still be functional even though it is located in intron five.  Individuals with 
schizophrenia were more than twice as likely to carry the GG genotype compared to the AA 
genotype for both the rs165774 and rs4680 SNPs.  This association was slightly improved 
when males were analysed separately possibly indicating a degree of sexual dimorphism.  
Our results confirm that COMT is a good candidate for schizophrenia risk, by replicating the 
association with rs4680 and identifying a novel SNP association. 
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Introduction 
Catechol-O-methyl transference (COMT) encodes a catabolic enzyme involved in the 
degradation of dopamine [1].  COMT (as well as 47 other genes) maps to a commonly deleted 
region on chromosome 22q11 [2].  When deleted, the region results in a marked increase in 
susceptibility to schizophrenia [3-5] making COMT a strong candidate gene for 
schizophrenia.  In addition, a polymorphism that results in a Val/Met substitution at codon 
158 (rs4680) results in altered activity levels of COMT [6].  Homozygotes for the Met allele 
have reduced COMT enzyme activity compared to homozygotes for the Val allele [7,8].  
While heterozygotes have intermediate enzyme activity indicating that a partially dominant 
mode of inheritance is operating [9].  One study suggests that the high activity Val allele may 
increase schizophrenia risk by increasing catabolism of dopamine in the prefrontal cortex 
[10].  The only other functional polymorphism that has been identified in COMT to be 
associated with altered enzyme activity is an Ala/Ser substitution at codon 72 (rs6267) [11].  
This polymorphism has only been found to be associated with schizophrenia and altered 
enzyme activity in Asian populations [11,12].   
 
Through linkage and association studies, COMT has been extensively investigated and 
association with schizophrenia has been established particularly for the rs4680 polymorphism 
[10,13-18].  However meta-analyses of COMT have not confirmed these associations.  A 
meta-analysis of case-control studies did not find association with the Val/Met polymorphism 
but association was observed in family-based linkage studies of European descent [19].  In a 
further meta-analysis study, association with Val/Met polymorphism and schizophrenia was 
found but when studies were excluded where controls departed significantly from Hardy-
Weinberg equilibrium, association was no longer observed [20].  A recent Japanese meta-
analysis did not report association of the Val/Met or Ala/Ser polymorphisms [21].   
 To identify novel polymorphism associations and confirm previous association studies, seven 
SNPs in COMT were selected that mark haplotype blocks, covering the entire COMT gene.  
These seven SNPs were then genotyped in an Australian population to investigate association 
with schizophrenia.   
 
Materials and methods 
Subjects 
The study included 160 Caucasian schizophrenia patients and 250 unrelated Caucasian 
controls.  Subjects were aged between 18 and 65 years.  Diagnostic and Statistical Manual of 
Mental Disorders-IV (DSM-IV) diagnosis of schizophrenia was confirmed by at least two 
independent psychiatrists.  These patients had never been diagnosed with other psychiatric 
disorders, including schizoaffective disorder, major depressive episode with psychotic 
features, or bipolar disorder.  No patients were treated with antidepressants, anxiolytic agents, 
or mood-stabilizing psychotropic medications and all were maintained on a constant dose of 
antipsychotic medication for a minimum of three weeks.  There were 22 females and 138 
males in the group diagnosed with schizophrenia with a mean age of 36.2 years (s.d. + 12.1 
years).  The mean age of patients at first diagnosis (onset of psychotic symptoms) was 23.4 
years (s.d. + 7.47 years).  They were being treated at the Royal Brisbane and Women’s 
Hospital, The Park Psychiatric Unit, and the Valley Community Psychiatric Centre.  The 
clinical sample was composed of 69 inpatients and 91 outpatients. All patients were 
administered the Positive and Negative Symptom Scale (PANSS) [22] to assess severity of 
psychotic features.  The PANSS total mean score was 45.013, SD. 13.646.  A history of 
psychological distress, indicated by past suicide attempt, was reported by 74 patients.  A total 
of 121 patients were able to provide information on psychiatric illness among first-degree 
relatives and 82 of these patients (68%) reported a positive family history of schizophrenia.  
This clinical sample was a group who had lived with schizophrenia for an average of 13 years 
since diagnosis continued to experience positive and negative symptoms despite treatment 
with antipsychotic medication.  Mean length of illness was 13.39 years, SD 10.91.  In 
addition the schizophrenia group contained a high proportion of individuals with a relatively 
severe history and/or a familial risk for psychosis. 
 
The control group consisted of 102 females and 148 males, with a mean age of 36.8 years 
(s.d. + 12.8 years).  The control group consisted mostly of medical and nursing staff recruited 
through hospitals, and university students and academic staff.  Formal screening for 
schizophrenia or other psychological disorders was not undertaken in the control population.  
As such, the controls represent an unselected control group. 
 
Each patient gave written informed consent.  Ethics approval was obtained from all 
institutions involved.   
 
Selection of SNPs 
Using the International HapMap Project (HapMap) phase II [23], five tag-SNPs in COMT 
with a minor allele frequency ≥0.2 were selected.  Tag-SNPs were identified using the pair-
wise option of Tagger with a threshold of r2 > 0.8.  Two non-synonymous SNPs reported in 




Oragene kits were used to extract DNA from saliva samples.  Samples were genotyped using 
a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility.  The hME assay is based on the annealing of an oligonucleotide primer 
(hME primer) adjacent to the SNP of interest. The addition of a DNA polymerase along with 
a mixture of terminator nucleotides allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products, each having a unique 
molecular mass. The resultant masses of the extension products are then analysed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
a genotype is assigned in real time. The hME assay was performed in multiplex with up to 36 
reactions in a single well.   
 
The genotyping of several other SNPs were independently verified by other methods such as 
real-time PCR with excellent correspondence (the COMT SNPs were not independently 
verified).  The genotyping fail rate for each SNP was:  rs165774 3%; rs4680 8%; rs737866 
5%; rs740603 6%; rs6267 4%; rs174675 4%.   
 
Statistical Analysis 
A Pearson’s chi-squared test was performed to identify statistical associations between 
alleles/genotype and schizophrenia status.  Odds ratios (OR) were also calculated.  Tests were 
performed on both genotype and allele data.  Statistical tests were performed using the 
COMPARE2 program from the WinPepi suite of epidemiology programs [24] and SPSS 
version 16.0.  Hardy-Weinberg equilibrium (HWE) was computed using Utility Programs for 
Analysis of Genetic Linkage [25].  The analysis of genotypes under a recessive model 
involved pooling the low-risk homozygotes and the heterozygotes and comparing frequencies 
with the high-risk homozygotes, i.e. OR > 1.  Correction for multiple testing was conducted 
using the Benjamini-Hochberg method [26].  Linkage disequilibrium and haplotype 
estimations were calculated using JLIN version 1.6.0 [27] 
 
Results 
In order to identify genetic association with schizophrenia, polymorphisms in the COMT 
gene were genotyped after selection using a haplotype block-based gene-tagging approach.  
A total of five tag-SNPs and 2 non-synonymous SNPs from NCBI were genotyped in a 
sample of 160 schizophrenia patients and 250 controls.  One of the non-synonymous SNPs, 
rs6267 (Ala72Ser) was excluded from the final analysis after genotyping revealed no 
heterogeneity in our patient or control populations.  Three of the remaining six SNPs 
analysed were found to be significantly associated with schizophrenia at the allele level 
(Table 1).  These included two tag-SNPs (rs165774 and rs4646316) and one non-
synonymous SNP (rs4680).  Both the rs165774 and rs4680 associations survived after 
correction for multiple testing but the rs4646316 association did not (corrected α-values 
varied between 0.025 and 0.008, for the two surviving significant SNPs).  These three SNPs 
were selected for further analysis at the genotype level (Table 2).  Only two of the SNPs, 
rs165774 and rs4680 remained significant at the genotype level.  However, all three SNPS 
were significant at the genotype level when analysed using the Mantel-Haenszel test for trend 
(partially dominant model) and all survived correction for multiple testing (corrected α-values 
varied between 0.05 and 0.017).  Interestingly, the strongest association at either the allele or 
genotype level was displayed by the intronic tag-SNP, rs165774.   
 
In the control and schizophrenia samples strong linkage disequilibrium (LD) was observed 
between all three pairs of loci (D' from 0.71-1).  The tightest linkage (D' = 1) was observed in 
the schizophrenia samples between the rs4646316 and rs165774 polymorphisms, which were 
separated in the gene sequence by only 429 bp.  The estimation of haplotype frequency for 
the three loci by an expectation-maximization algorithm revealed no statistically significant 
differences between the schizophrenia and control samples.   
 
Genotype frequencies indicated that all polymorphisms were in HWE in both case and 
control samples. 
 
Examination of the genotype odds ratios (OR) of the rs165774 and rs4680 SNPs suggests that 
a partially dominant mode of inheritance is operating for schizophrenia, i.e. the heterozygous 
OR was intermediate between the associated and non-associated genotypes (Table 2).     
 
In order to evaluate whether there was any sexual dimorphism in the population, the male 
schizophrenia patients were analysed separately from the female patients. At the allele level, 
the same three SNPS showed association with disease with slightly improved p-values 
(rs165774, Pearson χ2 = 8.929, p = 0.03; rs4646316, Pearson χ2 = 4.489, p = 0.034; rs4680, 
Pearson χ2 = 6.403, p = 0.011).  At the genotype level, rs165774 showed association with 
schizophrenia with a slightly improved p-value of 0.018 (Pearson χ2 = 7.985) and rs4680 had 
the same p-value of 0.044 (Pearson χ2 = 6.254).  The male schizophrenia samples remained in 
HWE.  The remaining female cases were too small in number to analyse meaningfully.   
 
Positive and negative symptom scale ratings and age of onset were also collected for each 
schizophrenia patient and correlated with genotype for each polymorphism.  Analysis of 
variance was performed on genotype versus PANSS positive rating scale, PANSS negative 
rating scale, PANSS general scale and PANSS total scale as well as onset age.  No significant 
associations were found.    
   
Discussion 
Analysis of five tag-SNPs and two non-synonymous SNPs in COMT revealed associations 
with schizophrenia at the genotype and allele level for two polymorphisms (rs165774 and 
rs4680) in an Australian schizophrenia cohort.  The rs4646316 SNP was also found to be 
significant but only at the allele level and the association did not hold up after correction for 
multiple testing.  Given our results and the fact that two other studies failed to identify an 
association with schizophrenia [28,29], rs4646316 is unlikely to be involved in susceptibility 
to schizophrenia.  The rs165774 has been analysed previously but an association with 
schizophrenia has not been identified [28-30].  We may have observed an association with 
schizophrenia and rs165774 because of the high heritability seen in our patient cohort.  In our 
study 68% of patients reported a positive family history of schizophrenia.  Our clinical 
sample was a group who had lived with schizophrenia for an average of 13 years since 
diagnosis and continued to experience positive and negative symptoms despite treatment with 
antipsychotic medication.  Therefore our samples consisted of a high proportion of 
individuals with a relatively severe history and familiar risk for schizophrenia.    
 
Previous results for the Val/Met (rs4680) SNP are more controversial with a number of 
positive associations [10,13-18,31-33] but also many negative associations with 
schizophrenia identified [11,18,28,29,34].  Our findings as well as numerous others support 
the Val/Met polymorphism as a risk factor for schizophrenia susceptibility.  Our results also 
support a partially dominant mode of inheritance for the rs4680 SNP which is consistent with 
an earlier study that found individuals who were heterozygous for rs4680 had intermediate COMT 
enzyme activity compared to homozygotes [9].  Failure of other studies to replicate the 
association of rs4680 with schizophrenia could be the result of clinical heterogeneity of the 
cases.   
In a Korean population an Ala72Ser polymorphism (rs6267) was found to be associated with 
schizophrenia but the Val/Met polymorphism was not associated [11].  The rs6267 
polymorphism displayed no heterogeneity in our Caucasian study suggesting that it is a racial 
marker.  In a Chinese population the rs4633 SNP (not analysed by us) was found to be 
significantly associated with schizophrenia but not rs4680 [30].  The Chinese study 
concluded that ethnic background might be one of the major reasons for the controversial 
results.  The SNP rs4633 has been shown to be in complete linkage disequilibrium with 
rs4680 in a European study [35] but the Chinese study did not observe LD in their 
population.  They concluded that rs4633 rather than rs4680 is likely to be the susceptibility 
SNP for schizophrenia in a Chinese population [30].   
Some evidence suggests that association between COMT and schizophrenia is different 
between men and women [33,36].  In addition, COMT enzyme activity in the prefrontal 
cortex is higher in men than women [6].  To address some of these differences we analysed 
males separately for COMT association with schizophrenia.  Despite reducing the number of 
samples in the analysis, the significance of association between all three SNPs and 
schizophrenia was not only maintained, it was slightly improved when only males were 
analysed.  This is consistent with at least a degree of sexual dimorphism in genetic 
susceptibility to schizophrenia in males.  This is perhaps not surprising considering the 
differences in schizophrenia environmental risk factors for males and females and the 
possibility that they might be acting on different susceptibility genes.  A recent study found 
association between the Val allele of the rs4680 SNP and schizophrenia in males but not 
females in a Spanish population [36].  They also observed a strong deviation from Hardy-
Weinberg equilibrium in their male population.  In contrast, an earlier Turkish study found 
association with the rs4680 SNP and schizophrenia to be stronger in females [37].   
 
The rs165774 SNP displayed stronger association than rs4680 at both the allele and genotype 
levels but it is in tight LD with the non-synonymous SNP rs4680.  Despite the fact that it is 
an intronic tag-SNP, it is still possible that rs165774 is functional or it is possible that it is in 
linkage disequilibrium with another nearby functional SNP such as rs737865 or rs165599 
[33,38].   
Conclusions 
In order to obtain optimal clinical homogeneity in our schizophrenia group, the clinical 
evaluation of patients from the same catchment area was performed by senior psychiatrists 
and diagnosis of schizophrenia (DSM-IV) was confirmed by at least two independent 
psychiatrists.  Control samples collected from the same catchment area as the cases were not 
screened for psychiatric conditions.  However not screening controls is unlikely to bias 
results as screening would only strengthen the associations observed between cases and 
controls.  Although cases and controls were screened for Caucasian ethnicity, population 
stratification can’t be ruled out.  However, our results for the rs4680 SNP have been 
confirmed by numerous other groups in Caucasian populations.  The other significant SNP, 
rs165774 ideally needs to be confirmed in other Caucasians groups as well as defined ethnic 
groups.  While our association study does not have an extremely large number of cases and 
controls, the numbers are still strong and we obviously had sufficient power to detect 
association.  Our numbers may not be sufficiently large enough to exclude association with 
the rs4646316 SNP and the p-value was approaching significance at the genotype level and 
was significant at the allele level.   
In summary we have confirmed association of the Val/Met polymorphism with schizophrenia 
in our Australian population and have demonstrated that rs165774 could also increase 
schizophrenia risk.   
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